City Therapeutics, Clinical-Stage RNAi Therapeutics Developer, Files for Nasdaq Global Market IPO

City Therapeutics, a clinical-stage biotechnology company developing RNA interference (RNAi) medicines, filed an S-1 to go public on the Nasdaq Global Market under the ticker CTY. The IPO is led by Goldman Sachs, Jefferies, Stifel and Oppenheimer. Proceeds will fund clinical trials for its lead pro…